Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells

• Published in: Molecular & cellular proteomics Vol. 17; no. 11; pp. 2197 - 2215
• Main Authors: Makjaroen, Jiradej, Somparn, Poorichaya, Hodge, Kenneth, Poomipak, Witthaya, Hirankarn, Nattiya, Pisitkun, Trairak
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-11-2018; The American Society for Biochemistry and Molecular Biology
• Subjects: Antigen Presentation; Antiviral Agents - metabolism; Cell Death; Computational Biology; dimethyl labeling; Down-Regulation; Hep G2 Cells; Hepatitis B virus - physiology; Hepatoblastoma - metabolism; Hepatoblastoma - pathology; Humans; Immunology; immunoproteasome; Interferons - metabolism; Mass Spectrometry; Models, Biological; Proteomics - methods; Quantification; quantitative proteomics; Reproducibility of Results; RIG-I; RNA, Messenger - genetics; RNA, Messenger - metabolism; Signal Transduction; Systems biology; Transfection; type III IFN; Up-Regulation; Virus Replication; Viruses; immunoproteasome; Immunology; Quantification; Systems biology; dimethyl labeling; Mass Spectrometry; Viruses; RIG-I; quantitative proteomics; type III IFN
• ISSN: 1535-9476; 1535-9484
• DOI: 10.1074/mcp.RA118.000735

Interferon lambda (IFN-λ) is a relatively unexplored, yet promising antiviral agent. IFN-λ has recently been tested in clinical trials of chronic hepatitis B virus infection (CHB), with the advantage that side effects may be limited compared with IFN-α, as IFN-λ receptors are found only in epithelial cells. To date, IFN-λ's downstream signaling pathway remains largely unelucidated, particularly via proteomics methods. Here, we report that IFN-λ3 inhibits HBV replication in HepG2.2.15 cells, reducing levels of both HBV transcripts and intracellular HBV DNA. Quantitative proteomic analysis of HBV-transfected cells was performed following 24-hour IFN-λ3 treatment, with parallel IFN-α2a and PBS treatments for comparison using a dimethyl labeling method. The depth of the study allowed us to map the induction of antiviral proteins to multiple points of the viral life cycle, as well as facilitating the identification of antiviral proteins not previously known to be elicited upon HBV infection (e.g. IFITM3, XRN2, and NT5C3A). This study also shows up-regulation of many effectors involved in antigen processing/presentation indicating that this cytokine exerted immunomodulatory effects through several essential molecules for these processes. Interestingly, the 2 subunits of the immunoproteasome cap (PSME1 and PSME2) were up-regulated whereas cap components of the constitutive proteasome were down-regulated upon both IFN treatments, suggesting coordinated modulation toward the antigen processing/presentation mode. Furthermore, in addition to confirming canonical activation of interferon-stimulated gene (ISG) transcription through the JAK-STAT pathway, we reveal that IFN-λ3 restored levels of RIG-I and RIG-G, proteins known to be suppressed by HBV. Enrichment analysis demonstrated that several biological processes including RNA metabolism, translation, and ER-targeting were differentially regulated upon treatment with IFN-λ3 versus IFN-α2a. Our proteomic data suggests that IFN-λ3 regulates an array of cellular processes to control HBV replication.